{'fraction_non_alphanumeric': 0.029045643153526972, 'fraction_numerical': 0.0, 'mean_word_length': 5.830188679245283, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Targeting LncRNAs in Cardiovascular Disease: Options and Expeditions

Nucleic acid-based therapeutics constitutes the next frontier in cardiovascular disease (CVD) management. Recent findings have shown a strong regulatory role of a new class of non-coding RNAs (ncRNAs) known as long ncRNAs (lncRNAs), on biological pathways, cell function, and cardiovascular tissue homeostasis in health and disease. Accumulating studies demonstrate that lncRNAs may regulate protein-coding genes, RNAs, and epigenetic factors in a tight spatial and temporal manner. Herein, we discuss key technical hurdles, current limitations and challenges as well as advantages and disadvantages of emerging experimental methods in the lncRNA field.